-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2024-512632-30-00
4
2021-12-02
X-linked hypohidrotic ectodermal dysplasia (XLHED)
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-516728-32-00
10
2021-10-29
Indolent Systemic Mastocytosis and SSM
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-517300-10-01
5
2020-12-17
Resectable diffuse type gastric and gastroesophageal junction Typ II/I
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2023-508251-39-00
5
2020-09-18
Psoriatic arthritis
-
2024-514962-38-00
1
2020-08-25
Solid Tumors
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2024-514494-21-00
4
2020-05-13
autoimmune encephalitis
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-509343-27-00
11
2019-10-28
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-503629-20-00
9
2018-06-27
Metastatic breast cancer, including triple negative breast cancer (TNB
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-518998-33-00
5
2025-07-23
Ulcerative Colitis
-
2024-516745-39-00
4
2025-07-11
Cutaneous lupus erythematosus
-
2022-503001-38-01
5
2025-07-08
HR-positive HER-2- negative Breast Cancer